Citations

Showing 10 of 108162 citations.

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Lai, Dongbing , Fontanillas, Pierre , Aasly, Jan , Beecham, Gary W. , Berg, Daniela , Bressman, Susan , Brockmann, Kathrin , Clark, Lorraine N. , Cookson, Mark , Das, Sayantan , Farrer, Matthew J. , Trinh, Joanne , Gasser, Thomas , Gustavsson, Emil K. , Klein, Christine , Langston, J. William, Lynch, Timothy , Marder, Karen, Martin, Eden R. , Mejia‐Santana, Helen, Molho, Eric , Nuytemans, Karen , Ozelius, Laurie J. , Raymond, Deborah , Ross, Owen A. , Samii, Ali, Saunders‐Pullman, Rachel , Schüle, Birgitt , Tolosa, Eduardo , Tomkins, James E. , Vilas, Dolores , Trojanowski, John Q. , Uitti, Ryan J. , Zabetian, Cyrus P. , Urtreger, Avi Orr, Cannon, P. F. , Fiske, Brian , Brockman, Kathrin , Klein, Christine , Ross, Owen A , Uitti, Ryan, Visanji, Naomi P , Zabetian, Cyrus P , Mirelman, Anat , Alipanahi, Babak , Schwantes-An, Tae-Hwi Linus , Alcalay, Roy N. , Brice, Alexis , Deerlin, Vivianna M. Van , Follett, Jordan , Goldwurm, Stefano , Lang, Anthony E. , Latourelle, Jeanne C. , Marras, Connie , McLean, Cory Y. , Myers, Richard H. , Payami, Haydeh , Rogaeva, Ekaterina A. , Rogers, Michael P. , Schulte, Claudia , Scott, William K. , Tanner, Caroline M. , Vance, Jeffery M. , Visanji, Naomi P. , Wszołek, Zbigniew K. , Giladi, Nir , Foroud, Tatiana

Mayo Clinic

Annals of Neurology | May 3, 2021 | Volume: 90 | Issue: 1 | Pages: 76-88

10.1002/ana.26094 | PMID 33938021 Get It

Objective The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. Methods We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. Results A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. Interpretation This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94
Determinants of pain interference and headache impact in patients who have chronic migraine with medication overuse: Results from the MOTS trial
Sahai‐Srivastava, Soma , Murinova, Natalia , Birlea, Marius , Ahmed, Zubair , Digre, Kathleen B. , Lopez, Kristina, Mullally, William J. , Blaya, Maike Tiede, Pippitt, Karly , Cutrer, F. Michael , DeLange, Justin M., Schecht, Howard, Lane, Judy, Wald, John J., Martin, Vincent T., Spare, Nicole , Hentz, Joseph G. , Robert, Teri, Investigators, on behalf of the MOTS, Pippitt, Karly , Sahai-Srivastava, Soma , Schwedt, Todd J. , Rizzoli, Paul B. , Cortez, Melissa , Dodick, David W. , Investigators, on behalf of the MOTS

Mayo Clinic

Cephalalgia | May 3, 2021 | Volume: 41 | Issue: 10 | Pages: 1053-1064

10.1177/03331024211006903 | PMID 33938249 Get It

Objective “Pain interference” and “headache impact” refer to negative consequences that pain and headache have on one’s life. This study investigated determinants of these negative impacts in a large patient cohort who have chronic migraine with medication overuse. Methods Six hundred and eleven adults were enrolled from 34 headache, neurology, and primary care clinics. Negative consequences of chronic migraine with medication overuse were determined using the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference 6b questionnaire and the Headache Impact Test 6. Relationships between PROMIS-6b and Headache Impact Test 6 scores with demographics, headache characteristics, medication use, anxiety symptoms, and depression symptoms were assessed with linear regression. Elastic Net regression was used to develop a multiple regression model. Results PROMIS-6b T-Scores averaged 65.2 (SD 5.4) and Headache Impact Test 6 scores averaged 65.0 (SD 5.3), indicating severe negative consequences of chronic migraine with medication overuse. Chronic migraine with medication overuse interfered with enjoyment of life, concentration, daily activities, doing tasks away from home, and socializing. Depression symptom severity had the strongest relationship with pain interference and headache impact. Moderate-to-severe headache frequency, headache intensity, and anxiety symptoms were also associated with pain interference and headache impact. Conclusions Chronic migraine with medication overuse is associated with substantial negative consequences, the extent of which is most strongly related to depression symptoms.
Generating a Social Media Ontology for Otology and Neurotology
Marinelli, John P. , Carlson, Matthew L. , Lustig, Lawrence R. , Kesser, Bradley W. , Antonelli, Patrick J. , Hong, Robert , Bowe, Sarah N.

Mayo Clinic

Otology & Neurotology | May 3, 2021 | Volume: 42 | Issue: 5 | Pages: 635-637

10.1097/mao.0000000000003170 | PMID 33935255 Get It

Synchronous pityriasis lichenoides et varioliformis acuta and lymphoplasmacytic lymphoma: a distinct association
Lang, Margaret E. , Farrell, Deenah, Comfere, Nneka I. , Lacy, Martha Q. , Sartori‐Valinotti, Julio C. , Farrell, Deenah N

Mayo Clinic

International Journal of Dermatology | May 2, 2021 | Volume: 60 | Issue: 12 | Pages: 1550-1552

10.1111/ijd.15636 | PMID 33934331 Get It

Treatment of cradle cap in infants with a new cosmetic non‐steroidal gel cream: Clinical, laboratory, and instrumental evaluation
Micali, Giuseppe , Pulvirenti, Nella, Dall’Oglio, Federica , Tedeschi, Aurora, Quattrocchi, Enrica , Lacarrubba, Francesco , Lacarrubba, Francesco

Mayo Clinic

Journal of Cosmetic Dermatology | May 2, 2021 | Volume: 20 | Issue: S1 | Pages: 14-17

10.1111/jocd.14095 | PMID 33934474 Get It

AbstractBackgroundCradle cap is a benign and self‐limiting variant of seborrheic dermatitis (SD) that can be distressing for parents.AimsTo assess by clinical/laboratory/instrumental evaluation the efficacy/tolerability of a gel cream containing piroctone olamine (antifungal), biosaccharide gum‐2 (antifungal), stearyl glycyrrhetinate (anti‐inflammatory), and zinc l‐pyrrolidone carboxylate (zinc‐PCA) (antiseborrheic) in the treatment of mild/ moderate cradle cap.MethodsIn this prospective, open‐label trial, 10 infants, with mild/moderate cradle cap enrolled at the Dermatology University Clinic of Catania (Italy) used the tested gel cream twice daily for 30 days. Degree of erythema was evaluated clinically by a 5‐point severity scale (from 0=no erythema to 4=severe erythema), at baseline, at 15 and 30 days. Desquamation was rated by dermoscopy evaluation using a 5‐point scale (from 0=no desquamation to 4=severe/many large adherent white flakes), at all time points. An Investigator Global Assessment (IGA) using a 6‐point scale (from −1=worsening to 4=complete response/clear) was also performed at 30 days. Five subjects, randomly selected, underwent double microbiological evaluation for bacteria and yeasts by cultures of cotton swabs at baseline and at 30 days. Tolerability/acceptability was evaluated on a 4‐point scale (from 0=very poor to 3=excellent) at 15 and 30 days. Data were processed using SAS version 9.ResultsAt baseline, a significant colony‐forming unit (CFU) count for Malassezia furfur and Staphylococcus aureus was detected in 4 out of 5 selected patients. After 15 and 30 days, a statically significant reduction from baseline in erythema and desquamation severity was observed, along with a reduction in CFU count for Malassezia furfur and Staphylococcus aureus from baseline. No signs of local side effects were documented.ConclusionsOur results indicate that the tested gel cream may represent a valid option to treat mild‐to‐moderate forms of cradle cap and support its antifungal and antibacterial properties.
Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer
Carr, Ryan M. , Jin, Zhaohui , Hubbard, Joleen M. , Hubbard, Joleen , Jin, Zhaohui , Carr, Ryan M

Mayo Clinic

Cancers | May 1, 2021 | Volume: 13 | Issue: 9 | Pages: 2180

10.3390/cancers13092180 | PMID 34062753 Get It

Anal squamous cell carcinoma (ASCC) is a rare malignancy, with most cases associated with human papilloma virus and an increased incidence in immunocompromised patients. Progress in management of ASCC has been limited not only due to its rarity, but also the associated lack of research funding and social stigma. Historically, standard of care for invasive ASCC has been highly morbid surgical resection, requiring a permanent colostomy. Surgery was associated with disease recurrence in approximately half of the patients. However, the use of chemotherapy (5-fluorouracil and mitomycin C) concomitantly with radiation in the 1970s resulted in disease regression, curing a subset of patients and sparing them from morbid surgery. Validation of the use of systemic therapy in prospective trials was not achieved until approximately 20 years later. In this review, advancements and shortcomings in the use of systemic therapy in the management of ASCC will be discussed. Not only will standard-of-care systemic therapies for locoregional and metastatic disease be reviewed, but the evolving role of novel treatment strategies such as immune checkpoint inhibitors, HPV-based vaccines, and molecularly targeted therapies will also be covered. While advances in ASCC treatment have remained largely incremental, with increased biological insight, an increasing number of promising systemic treatment modalities are being explored.
The transseptal puncture experience: Safety insights from FDA MAUDE database
Morcos, Ramez , Desai, Anand , Alkhouli, Mohamed, Saad, Marwan , Luna, Michael , García, Santiago , Khalili, Houman , Maini, Brijeshwar , Saad, Marwan , Garcia, Santiago , Khalili, Houman , Megaly, Michael S. , Maini, Brijeshwar

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 1, 2021 | Volume: 98 | Issue: 6 | Pages: No page available

10.1002/ccd.29746 | PMID 33932271 Get It

AbstractBackgroundThere is a paucity of literature on safety and efficacy of various transseptal puncture (TSP) needles.ObjectivesTo assess the reported mechanisms of failure, complications, and outcomes among the most frequently used transseptal needles in the United States.MethodsWe queried the Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database between January 2011 and January 2021 for reports on the most commonly used transseptal needles: NRG (Baylis Medical, Montreal, Canada), and BRK (St. Jude, Saint Paul, MN)]. The primary outcome was the mechanism of failure. Secondary outcomes included clinical consequences of device failure.ResultsThe final analysis included 306 reports of failure/complication with TSP needles (NRG n = 70, BRK n = 236). The most commonly reported mode of failure was detachment of the needle component (i.e., clip, hub, stopcock, shaft, spring, or needle tip) (14.7% overall; 17.8% BRK; and 4.3% NRG). Among these reports, cardiac perforation was the most common complication (69.9% overall; 69.1% for BRK; and 72.9% for NRG). Pericardiocentesis was the second most commonly reported complication (45.1% overall; 48.3% for BRK; and 34.3% for NRG). The procedure was successfully completed in 33.3% of all cases (36.4% for BRK and 22.9% for NRG), while surgical conversion was needed in (13.4% overall; 14% for BRK and 11.4% for NRG) of the reports. Death occurred in 3.9% of all cases overall (3.4% for BRK and 5.7% for NRG).ConclusionsNeedle detachment was the most common mode of failure, and cardiac perforation was the most common complication reported with TSP needles. Future efforts should focus on innovative TSP needle design, best practice guidelines, including role of imaging guidance, and increased TSP training.
Clarity on the Use of Glucose Meters for Critically Ill Hospitalized Patients, But One Big Question Remains to be Answered
Karon, Brad S.

Mayo Clinic

The Journal of Applied Laboratory Medicine | May 1, 2021 | Volume: 6 | Issue: 4 | Pages: 813-815

10.1093/jalm/jfab050 | PMID 34089609 Get It

Carbon fiber–reinforced PEEK instrumentation in the spinal oncology population: a retrospective series demonstrating technique, feasibility, and clinical outcomes
Neal, Matthew T. , Richards, Alexandra E. , Curley, Kara L. , Ashman, Jonathan B. , Vora, Sujay A., Kalani, Maziyar A. , Patel, Naresh P.

Mayo Clinic

Neurosurgical Focus | May 1, 2021 | Volume: 50 | Issue: 5 | Pages: E13

10.3171/2021.2.focus20995 | PMID 33932921 Get It

OBJECTIVE The authors aimed to demonstrate the feasibility and advantages of carbon fiber–reinforced PEEK (CFRP) composite implants in patients with both primary and secondary osseous spinal tumors. METHODS Twenty-eight spinal tumor patients who underwent fixation with CFRP hardware were retrospectively identified in a Spine Tumor Quality Database at a single institution. Demographic, procedural, and follow-up data were retrospectively collected. RESULTS The study population included 14 females and 14 males with a mean age of 60 years (range 30–86 years). Five patients had primary bone tumors, and the remaining patients had metastatic tumors. Breast cancer was the most common metastatic tumor. The most common presenting symptom was axial spine pain (25 patients, 89%), and the most common Spine Instability Neoplastic Score was 7 (range 6–14). Two patients in this series had anterior cervical procedures. The remaining patients underwent posterior thoracolumbar fixation. The average fusion length included 4.6 vertebral segments (range 3–8). The mean clinical follow-up time with surgical or oncology teams was 6.5 months (range 1–23 months), and the mean interval for last follow-up imaging (CT or MRI) was 6.5 months (range 1–22 months). Eighteen patients received postoperative radiation at the authors’ institution (16 with photon therapy, 2 with proton therapy). Eleven of the patients (39%) in this series died. At the last clinical follow-up, 26 patients (93%) had stable or improved neurological function compared with their preoperative status. At the last imaging follow-up, local disease control was observed in 25 patients (89%). Two patients required reoperation in the immediate postoperative period, one for surgical site infection and the other for compressive epidural hematoma. One patient was noted to have lucencies around the most cephalad screws 3 months after surgery. No hardware fracture or malfunction occurred intraoperatively. No patients required delayed surgery for hardware loosening, fracture, or other failure. Early tumor recurrence was detected in 3 patients. Early detection was attributed to the imaging characteristics of the CFRP hardware. CONCLUSIONS CFRP spinal implants appear to be safe and comparable to conventional titanium implants in terms of functionality. The imaging characteristics of CFRP hardware facilitate radiation planning and assessment of surveillance imaging. CFRP hardware may enhance safety and efficacy, particularly with particle therapy dosimetry. Larger patient populations with longer-term follow-up are needed to confirm the various valuable aspects of CFRP spinal implants.
Feasibility of achieving planned surgical margins in primary spine tumor: a PTRON study
Dandurand, Charlotte , Fisher, Charles G. , Rhines, Laurence D. , Charest-Morin, Raphaële , Luzzati, Alessandro , Reynolds, Jeremy , Wei, Feng , Gokaslan, Ziya L. , Sciubba, Daniel M. , Lazáry, Áron , Kawahara, Norio , Rampersaud, Y. Raja , Disch, Alexander C. , Chou, Dean , Hornicek, Francis J. , Laufer, IIya, Sahgal, Arjun , Dea, Nicolas , Reynolds, Jeremy , Reynolds, Jeremy , Lazary, Aron , Boriani, Stefano , Gasbarrini, Alessandro , Bettegowda, Chetan , Clarke, Michelle J. , Shin, John H.

Mayo Clinic

Neurosurgical Focus | May 1, 2021 | Volume: 50 | Issue: 5 | Pages: E16

10.3171/2021.2.focus201091 | PMID 33932923 Get It

OBJECTIVE Oncological resection of primary spine tumors is associated with lower recurrence rates. However, even in the most experienced hands, the execution of a meticulously drafted plan sometimes fails. The objectives of this study were to determine how successful surgical teams are at achieving planned surgical margins and how successful surgeons are in intraoperatively assessing tumor margins. The secondary objective was to identify factors associated with successful execution of planned resection. METHODS The Primary Tumor Research and Outcomes Network (PTRON) is a multicenter international prospective registry for the management of primary tumors of the spine. Using this registry, the authors compared 1) the planned surgical margin and 2) the intraoperative assessment of the margin by the surgeon with the postoperative assessment of the margin by the pathologist. Univariate analysis was used to assess whether factors such as histology, size, location, previous radiotherapy, and revision surgery were associated with successful execution of the planned margins. RESULTS Three hundred patients were included. The surgical plan was successfully achieved in 224 (74.7%) patients. The surgeon correctly assessed the intraoperative margins, as reported in the final assessment by the pathologist, in 239 (79.7%) patients. On univariate analysis, no factor had a statistically significant influence on successful achievement of planned margins. CONCLUSIONS In high-volume cancer centers around the world, planned surgical margins can be achieved in approximately 75% of cases. The morbidity of the proposed intervention must be balanced with the expected success rate in order to optimize patient management and surgical decision-making.